他汀导致肝酶升高63例回顾性分析  

Retrospective Analysis of Elevated Liver Transaminase Levels Caused by Statins

作　　者：王颖[1] 王吉云[1] 

机构地区：[1]首都医科大学附属北京同仁医院心血管中心,北京100730

出　　处：《中国医药导刊》2011年第2期267-268,共2页Chinese Journal of Medicinal Guide

摘　　要：目的:分析他汀治疗后出现肝酶升高的相关因素及其转归,评价他汀的肝脏安全性。方法:回顾性总结2007～2010年我院收治的63例服他汀后肝酶升高患者的临床资料,选取63例服他汀后肝酶正常的患者作为正常对照。结果:肝酶升高组较正常组应用较大剂量他汀的比例明显增加(P<0.05),前者的转氨酶基线水平较后者升高(P=0,00),而两组的性别、年龄、BMI、LDL-C降幅、总胆红素水平、他汀的种类、合并用药、合并的肝胆疾病未见显著性差异。3个月后肝酶升高组均恢复至正常转氨酶水平,肝酶明显升高时他汀的停药率增加(P<0.05)。结论:他汀治疗后出现肝酶升高,通常是无症状、可逆的,呈剂量依赖性,总体上他汀是安全的,有待于更充分合理的应用。Objective： To investigate the relative factors and prognosis of elevated liver transaminase levels after statin therapy. Methods：We retrospectively analysed the clinical data of 63 cases with elevated liver transaminase values caused by statins in our hospital from 2007 to 2010. Results： The group of elevated transaminase had higher dose of statin and higher baseline of transaminase level than control group（P〈0.05）, had no difference in sex, age, BMI, LDL-C reduction, total bilirubin level, type of statin, coadministration and concomitant liver and gallbladder disease with control group and had normal transaminase values after 3 months of discharge. The ration of statin withdrawal in group of marked aminotransferase elevations statistically increased（P〈0.05）. Conclusions：The elevation of liver transaminase after statin use is usually asymptomatic, reversible, and dose-related. Overall statin is safe and statin utilization should be more sufficient and reasonable.

关 键 词：他汀 肝脏毒性 转氨酶 安全性 

分 类 号：R96[医药卫生—药理学]